17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Talking the talk alone is no longer enough for pharma companies where their digital strategies are concerned—now they need to walk the walk, too. 24 October 2022
Following its previous rejection of Sumitomo Pharma’s full acquisition proposal, endocrinology specialist Myovant Sciences has now accepted an increased offer from the Japanese major, with the news pushing its shares up 9% to $26.72 this morning. 24 October 2022
US vaccine developer Vaxcyte roared up 79% to $20.58 in pre-market trading today, as the company revealed encouraging early-stage results with its investigational pneumococcal vaccine. 24 October 2022
The UK's National Institute for Health and Care Excellence (NICE) has recommended the use of Ryeqo (relugolix/estradiol/norethisterone) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. 24 October 2022
New Jersey, USA-based cancer giant Bristol Myers Squibb has had its bid to broaden the label for Camzyos (mavacamten) accepted by the US regulator. 24 October 2022
The Russian government is planning to take measures to prevent a shortage of anti-HIV drugs in the country by the increased procurements drugs and their more active supplies to the domestic market, reports The Pharma Letter’s local correspondent. 24 October 2022
Global drugmakers continue their operations in Russia, despite its ongoing military conflict with Ukraine and the ever deteriorating economic situation in the country, according to recent statements by some Russian senior state officials and local media, reports The Pharma Letter’s local correspondent. 24 October 2022
Shares of US drug developer Matinas BioPharma shot up more than 22% to $0.85 on Friday, when it announced positive interim data from Cohort 4, the fourth and final cohort of the Phase II EnACT trial evaluating MAT2203, an oral LNC formulation of amphotericin B, for the treatment of cryptococcal meningitis. 24 October 2022
In August, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Sunlenca (lenacapavir) injection and tablets, alongside other antiretrovirals, in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. 21 October 2022
Boston, Massachusetts-based non-profit The Institute for Clinical and Economic Review (ICER) has issued its final report into the cost-effectiveness of the latest generation of weight loss treatments. 21 October 2022
Intelligence company Evaluate predicts sales in the global pharmaceutical industry to grow by 6% per year between 2022 and 2028, according to its annual World Preview report. 21 October 2022
Positive safety and efficacy data from a pivotal Phase III clinical trial have just been published in leading nephrology journal Kidney International, and lend further support to the recent European launch of Kinpeygo (budesonide; development name: Nefecon). 21 October 2022
USA-based CNS specialist Corium and Gurnet Point Capital have announced the acquisition of their manufacturing business and a $100 million equity investment by Webster Equity Partners. 21 October 2022
Japanese gastroenterology giant Takeda has inked a deal with German firms Zedira and Dr. Falk Pharma for the development of a celiac disease candidate, TAK-227. 20 October 2022
The US Food and Drug Administration’s (FDA) Obstetrics, Reproduction and Urologic Advisory Committee yesterday voted to recommend that the FDA pursue withdrawal of approval of privately-held Swiss drugmaker Covis Pharma’s Makena (hydroxyprogesterone caproate injection), the only FDA-approved treatment to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth. 20 October 2022
The recent European Commission’s (EC) approval of Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treated diseases, including obesity. 19 October 2022
Shares in Texan protein expert Salarius Pharmaceuticals fell back by as much as 45% on Monday, after the firm said it was pausing a key trial of its lead candidate. 19 October 2022
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.